摘要
睾丸生殖细胞肿瘤(TGCT)是15-35岁男性中最常见的恶性肿瘤.由于这些肿瘤的生物学和临床特点,可以作为研究顺铂耐药相关分子机制的合适系统。本文从临床和分子的角度对治疗耐药进行了综述。顺铂耐药是由多种生物学机制决定的,包括肿瘤细胞DNA修复能力的调节、凋亡细胞死亡途径的改变、基因表达途径的解除、表观基因的改变和DNA结合不足等。此外,本文还将TGCT描述为研究肿瘤干细胞在转移过程中的细胞特征的模型系统,并描述了可用于研究TGCT治疗耐药的实验模型。上述各方面有助于阐明顺铂耐药的分子机制,并有助于确定有前途的新的治疗靶点。
关键词: 睾丸生殖细胞肿瘤,顺铂耐药,分子机制,实验模型,癌症,肿瘤干细胞。
图形摘要
Current Cancer Drug Targets
Title:Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications
Volume: 18 Issue: 10
关键词: 睾丸生殖细胞肿瘤,顺铂耐药,分子机制,实验模型,癌症,肿瘤干细胞。
摘要: Testicular germ cell tumors (TGCTs) represent the most common malignancy in men aged 15-35. Due to these tumors’ biological and clinical characteristics, they can serve as an appropriate system for studying molecular mechanisms associated with cisplatin-based treatment resistance. This review describes treatment resistance from clinical and molecular viewpoints. Cisplatin resistance is determined by various biological mechanisms, including the modulation of the DNA repair capacity of cancer cells, alterations to apoptotic cell death pathways, deregulation of gene expression pathways, epigenetic alterations and insufficient DNA binding. Moreover, this review describes TGCTs as a model system that enables the study of the cellular features of cancer stem cells in metastatic process and describes experimental models that can be used to study treatment resistance in TGCTs. All of the abovementioned aspects may help to elucidate the molecular mechanisms underlying cisplatin resistance and may help to identify promising new therapeutic targets.
Export Options
About this article
Cite this article as:
Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications, Current Cancer Drug Targets 2018; 18 (10) . https://dx.doi.org/10.2174/1568009618666180102103959
DOI https://dx.doi.org/10.2174/1568009618666180102103959 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Targeted Delivery of Bleomycin: A Comprehensive Anticancer Review
Current Cancer Drug Targets Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery Human Model Neurons in Studies of Brain Cell Damage and Neural Repair
Current Molecular Medicine Estrogenic Effect of <i>Salvia officinalis</i> Extract on Reproductive Function of Female Mice and Identification of Its Phenolic Content
Combinatorial Chemistry & High Throughput Screening Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Current Cancer Therapy Reviews Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry Possible Protective Effects of Curcumin <i>via</i> Modulating of Androgen Receptor (AR) and Oct2 Gene Alterations in Cisplatin-Induced Testicular Toxicity in Rat
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Design and Development of Nanoemulsion Systems Containing Interferon Gamma
Protein & Peptide Letters Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines
Current Pharmacogenomics and Personalized Medicine Current State of the Art of New Tubulin Inhibitors in the Clinic
Current Clinical Pharmacology Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology Natural Carriers for siRNA Delivery
Current Pharmaceutical Design Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology The Male Peripubertal Phase as a Developmental Window for Reproductive Toxicology Studies
Current Pharmaceutical Design